Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib + Azacitidine in Newly Diagnosed IDH1m AML
NCT05907057Phase 3Recruiting
- Sponsor
- Servier
- Start
- Jun 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML), sponsored by Servier. Primary endpoints: Number of Adverse Events, Number of Serious Adverse Events and 9 more. Started Jun 2023; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05907057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907057.